Phase 3 N=129 Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
Osteoarthritis, Knee
Primary: Mean Standardized Change in Synovial Volume (SV) at 6 Weeks — -0.67; -0.9 Standardized Units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,060 Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
Breast Neoplasms
Primary: Disease-free Survival (DFS) Events — 127; 112 events
Phase 3 N=915 Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15) — -0.4049; -0.1574 score on a scale
Phase 3 N=40 Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
Parenteral Nutrition Associated Cholestasis
Primary: Number of Participants With Parenteral Nutrition Associated Cholestasis — 6; 6 Participants — p=0.94
Phase 3 N=905 Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15) — -0.3812; -0.2371 score on a scale
Phase 3 N=83 Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
Children and Adolescent With Type 2 Diabetes
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period) — -0.36; 0.49 percentage (% HbA1c) — p=0.012
Phase 3 N=155 Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery
Pain
Primary: Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores — 136.431; 254.119 cm*hr — p=<0.0001
Phase 3 N=72 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
Type 2 Diabetes
Primary: Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24 — -0.25; 0.50 Percentage of HbA1c — p=0.101
Phase 3 N=616 Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC
Hepatic Neoplasm Malignant Recurrent
Primary: Recurrence-free Survival — 809.0; 751.0 Days — p=0.351
Phase 3 N=39 Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation
Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 12 Weeks Post Quit Date — 7 Participants
Phase 3 N=122 Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Type 2 Diabetes
Primary: Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 — 0.11; 0.38 percentage (%HbA1c) — p=0.444
Phase 3 N=232 Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty
Pain
Primary: Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores Through 72 Hours — 259.545; 250.998; 279.794 cm*hr — p=0.4463
Phase 3 N=674 Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
Intra Abdominal Infections
Primary: Percentage of Participants With Clinical Success — 85.5; 90.2 percentage of participants
Phase 3 N=363 Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
Influenza
Primary: Time to Clinical Improvement — 97.5; 100.2 hours — p=0.4666
Phase 3 N=166 Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Primary: Time to First Confirmed Clinical Relapse — 39.14; 75.29 weeks — p=0.2949